Welcome to our dedicated page for Encompass Health SEC filings (Ticker: EHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Encompass Health Corporation’s (NYSE: EHC) SEC filings, offering detailed insight into the company’s inpatient rehabilitation hospital business and financial profile. As the largest owner and operator of inpatient rehabilitation hospitals in the United States, Encompass Health uses its filings to report operating results, liquidity measures and other material information.
Current reports on Form 8-K included in the available information show how the company discloses quarterly financial results, updates to full-year guidance and investor materials. These filings reference metrics such as net operating revenue, Adjusted EBITDA, adjusted earnings per share, leverage ratio and adjusted free cash flow, along with explanations of why non-GAAP measures are used and how they are reconciled to comparable GAAP figures.
Other 8-K filings address topics like publication of an Investor Reference Book, which provides an overview of the company and its industry, business outlook, growth strategy and operational initiatives, as well as Regulation FD communications when senior management meets with investors and analysts. Governance-related 8-Ks can also appear, such as notices of director departures.
Through this filings page, users can review Encompass Health’s earnings-related 8-Ks, Regulation FD disclosures and other material event reports as they are made available via EDGAR. AI-powered tools on the platform can help summarize lengthy documents, highlight key metrics and clarify definitions of non-GAAP measures like Adjusted EBITDA and adjusted free cash flow, making it easier to understand how the company evaluates performance, manages leverage and plans for growth.
For anyone analyzing EHC stock, these SEC filings are a primary source for understanding Encompass Health’s financial condition, risk disclosures, capital structure and strategic communications with investors.
Encompass Health Corp Chief Accounting Officer Andrew L. Price reported two tax-related share dispositions under an equity award. On
According to the footnote, these shares were withheld or surrendered to pay tax withholding obligations triggered by the vesting of related restricted stock, rather than sold as discretionary open-market trades. After these transactions, Price directly owned 75,405 shares of Encompass Health common stock.
Encompass Health Corp executive John Patrick Darby reported routine tax-related share dispositions. On
Encompass Health Corp EVP & Chief Financial Officer Douglas E. Coltharp reported tax-related share dispositions in Encompass Health Common Stock. On February 20, 2026, 674 shares were withheld at
According to the footnote, these shares were withheld or surrendered to pay tax withholding obligations tied to the vesting of restricted stock, rather than sold in open-market transactions. After these dispositions, Coltharp directly owned 84,971 shares, with additional indirect holdings reported through irrevocable trusts and a spouse.
Encompass Health Corp EVP and COO Patrick William Tuer reported two tax-related share dispositions tied to restricted stock vesting. On
Encompass Health Corporation filed an amended report to update a recent Board change. The Board had unanimously approved the appointment of Cain A. Hayes as a director on January 30, 2026. The amendment notes that on February 19, 2026, the Board appointed Mr. Hayes to the Compensation and Human Capital Committee and the Compliance and Quality of Care Committee. This filing supplements an earlier report originally filed on February 2, 2026, by providing these committee assignments for the new director.
Encompass Health Corp Chief Medical Officer Elissa Joy Charbonneau reported stock awards in the company’s common stock. On February 18, 2026, she acquired 8,914 shares at $0.00 per share as an annual restricted stock award under the 2025 Omnibus Performance Incentive Plan. On February 19, 2026, she acquired an additional 1,884 shares of restricted stock at $0.00 per share upon satisfaction of performance criteria from a performance share unit award granted on February 23, 2023. Following these grants, she directly owned a total of 22,756.061 shares of Encompass Health common stock.
Encompass Health Corp executive John Patrick Darby, EVP, General Counsel & Secretary, reported two stock awards. On February 18, 2026, he acquired 17,720 shares of common stock, and on February 19, 2026, he received 2,154 restricted shares. Following these grants, he directly holds 99,584 shares of Encompass Health common stock.
Encompass Health Corp EVP & Chief Financial Officer Douglas E. Coltharp reported stock awards in Encompass Health Common Stock. On February 18, 2026, he acquired 37,588 shares as an annual restricted stock award pursuant to the Corporation's 2025 Omnibus Performance Incentive Plan. On February 19, 2026, he acquired an additional 4,430 restricted shares upon satisfaction of performance criteria from a performance share unit award granted on February 23, 2023. After these grants, his directly held stake increased to 102,353 shares, and the filing also notes indirect holdings through irrevocable trusts and his spouse.
Encompass Health Corp reported stock awards to Chief Accounting Officer Andrew L. Price. He acquired 8,178 shares of Encompass Health common stock on February 18, 2026 and 1,560 shares on February 19, 2026, both at a stated price of $0.00 per share.
The 8,178-share issuance reflects restricted stock delivered after meeting performance criteria from a February 23, 2023 performance share unit award. The 1,560-share grant is an annual restricted stock award under the company’s 2025 Omnibus Performance Incentive Plan.
Encompass Health Corp reported that President and CEO Mark J. Tarr acquired company stock through equity awards, rather than open-market purchases. On February 19, 2026, he received 12,796 shares of Encompass Health common stock at $0.00 per share, increasing his direct holdings to 490,812 shares. This issuance of restricted stock resulted from meeting performance criteria under a performance share unit award granted on February 23, 2023.
On February 18, 2026, Tarr was also granted 100,946 shares of restricted stock at $0.00 per share, bringing his direct ownership to 478,016 shares immediately after that grant. This award was an annual restricted stock grant made under the corporation's 2025 Omnibus Performance Incentive Plan.